DEXCO S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.920 BRL | -3.44% |
|
+0.34% | -0.67% |
| Jan. 02 | Dexco S.A.(BOVESPA:DXCO3) dropped from Brazil IBRX Index | CI |
| Nov. 07 | Dexco S.A., Q3 2024 Earnings Call, Nov 07, 2024 |
Summary: Dexco S.A.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Dexco S.A.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses: Dexco S.A.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings Chart: Dexco S.A.
Source: Surperformance
ESG chart: Dexco S.A.
Source: MSCI
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 815M | |||||
| 8.08B | |||||
| 2.87B | |||||
| 2.06B | |||||
| 1.22B | |||||
| 1.16B | |||||
| 606M | |||||
| - | 547M | ||||
| 470M | |||||
| 400M | |||||
| Average | 1.82B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG MSCI
AA
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
ESG
Environment
Social
Governance
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- DXCO3 Stock
- Ratings Dexco S.A.